This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Meyer, F. Articles by Hercberg, S. Search for Related Content PubMed PubMed Citation Articles by Meyer, F. Articles by Hercberg, S.

A Prospective Study of the Insulin-Like Growth Factor Axis in Relation with Prostate Cancer in the SU.VI.MAX Trial

¹ Laval University Cancer Research Center; ² the Centre Hospitalier Universitaire de Québec, Quebec, Canada; and ³ Institut National de la Sante et de la Recherche Medicale, Paris, France

Requests for reprints: François Meyer, Centre de Recherche, Cancer Research Center, Laval University de Quebec, CHUQ, HDQ, 11 Cote Du Palais, Quebec, Canada G1R 2J6. Phone: 418-525-4444-15581; Fax: 418-691-5562. E-mail: francois.meyer{at}chuq.qc.ca

Several epidemiologic studies have examined with diverging results the relationships between circulating levels of insulin-like growth factors (IGF) and of IGF-binding proteins (IGFBP) and prostate cancer risk. We assessed the association of prediagnostic plasma levels of IGF-I, IGF-II, IGFBP-2, and IGFBP-3 and subsequent occurrence of prostate cancer in a case-control study nested in the SU.VI.MAX trial. The SU.VI.MAX study was a primary prevention trial testing a daily supplementation with low-dose antioxidant vitamins and minerals in male and female middle-aged volunteers in France. One hundred prostate cancer cases were diagnosed among 4,855 SU.VI.MAX participants over a 9-year follow-up period. For each case, four age-matched controls were selected randomly. Frozen baseline plasma samples were used to measure IGF-I, IGF-II, IGFBP-2, and IGFBP-3. Conditional logistic regression was used to assess the association between these four biochemical markers and prostate cancer risk. After controlling for the intervention group in the trial and the other IGF axis variables, the odds ratios and 95% confidence interval (95% CI) comparing the upper quartile to the baseline quartile were 1.83 (95% CI, 0.85-3.95), 1.05 (95% CI, 0.35-3.18), 0.79 (95% CI, 0.39-1.58), and 0.42 (95% CI, 0.12-1.52) for IGF-I, IGF-II, IGFBP-2, and IGFBP-3, respectively. More suggestive associations for IGF-I and IGFBP-3 were observed with advanced and aggressive cancers. Our results are consistent with those of some previous prospective studies and suggest that IGF axis variables are not long-term predictors of the occurrence of prostate cancer.

This article has been cited by other articles:

				M. Anzo, L. J. Cobb, D. L. Hwang, H. Mehta, J. W. Said, S. Yakar, D. LeRoith, and P. Cohen Targeted Deletion of Hepatic Igf1 in TRAMP Mice Leads to Dramatic Alterations in the Circulating Insulin-Like Growth Factor Axis but Does Not Reduce Tumor Progression Cancer Res., May 1, 2008; 68(9): 3342 - 3349. [Abstract] [Full Text] [PDF]

				N. E. Allen, T. J. Key, P. N. Appleby, R. C. Travis, A. W. Roddam, S. Rinaldi, L. Egevad, S. Rohrmann, J. Linseisen, T. Pischon, et al. Serum Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3 Concentrations and Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1121 - 1127. [Abstract] [Full Text] [PDF]